Drug Search Results
More Filters [+]

Danaparoid sodium

Alternative Names: danaparoid sodium, orgaran
Latest Update: 2022-12-08
Latest Update Note: Clinical Trial Update

Product Description

Danaparoid sodium (Orgaran, Organon) is a heparinoid glycosamino-glycuronan antithrombotic agent approved for the prophylaxis of post-operative deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing elective hip replacement surgery. Danaparoid is a low molecular weight heparinoid consisting of a mixture of heparan sulphate (84%), dermatan sulphate (12%) and small amounts of chondroitin sulphate (4%), whose antithrombotic activity has been well established. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11249517/)

Mechanisms of Action: AT III Activator,Factor Xa Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | France | Germany | Italy | New Zealand | Portugal | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Aspen Global
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Danaparoid sodium

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

09/08/2020

News Article

Mylan to Acquire Aspen's Thrombosis Business in Europe